Higher C. Diff Rates Linked to Vancomycin for Bowel Disease Patients

A study has linked initial vancomycin monotherapy to higher rates of Clostridium difficile infection in patients with inflammatory bowel disease, according to a report by Internal Medicine News.

The study, presented at Digestive Disease Week, also linked steroid use within three months of the infection to a higher recurrence rates of C. Difficile infection.


Researchers said the link between vancomycin and C. Difficile recurrence may have something to do with the severity of inflammatory bowel disease, and after treatment there may also be increased rates of vancomycin-resistant enterococcus infection that could affect the microbiome.


Read the Internal Medicine News report on inflammatory bowel disease.


Related Articles on Inflammatory Bowel Disease:

FDA Approves Dificid Tablets for C. Difficile Infection

C. Diff Increases Risk of Death 6-Fold in Inflammatory Bowel Disease Patients

Study: Antibiotic Therapy Could Induce Remission of Inflammatory Bowel Disease


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast